TRex Bio priced a $117 million IPO (TRXB) to fund early clinical development of regulatory T cell–targeting immunotherapies in autoimmune and inflammatory disease. The company is building around TRB-061, a fusion protein aimed at activating tumor necrosis factor receptor 2 on Tregs, with topline data expected in 2027.